In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Pharmacological properties

Emoxypine stabilizes the cell membrane, inhibits platelet and neutrophil aggregation, reduces the coagulation index, lengthens blood coagulation time, reduces blood viscosity, exhibits fibrinolytic activity, increases the content of cyclic nucleotides in tissues, and reduces the permeability of the vascular wall. Emoxypine also exhibits angioprotective properties, protects the retina from damage when exposed to high-intensity light, improves microcirculation.

Pharmacokinetics Emoxypine is excreted from the body mainly with urine and in small quantities - unchanged.

With retrobulbar administration, Emoxypine is almost instantly detected in the blood; during the first 2 hours, its concentration decreases sharply and after 24 hours the drug is absent in the blood. In the tissues of the eye, the concentration of Emoxypine is higher than in the blood.


Subconjunctival and intraocular hemorrhages of various origins. angioretinopathy (including diabetic retinopathy). central and peripheral choreoretinal dystrophy. thrombosis of the central retinal vein and its branches. complicated myopathy. angiosclerotic macular degeneration (dry form). detachment of the choroid in patients with glaucoma in the postoperative period. dystrophic diseases of the cornea. injuries, burns to the cornea. protection of the cornea (when using contact lenses) and the retina of the eye from high-intensity light (sunlight, laser radiation during laser coagulation).


The Emoxypine solution is administered subconjunctively or parabulbarno. retrobulbar administration is possible if necessary. 0.2–0.5 ml (2–5 mg) are administered subconjunctively, 0.5–1 ml (5–10 mg) of 1% solution is parabulbar. the drug is used for 10-30 days 1 time per day or every other day. if necessary, treatment can be repeated 2-3 times a year. retrobulbarly injected 0.5-1 ml of the drug 1 time per day for 10-15 days.

To protect the retina during laser coagulation (especially when laser coagulation restricts or destroys the tumor), 0.5–1 ml of Emoxypine is administered parabulbarly or retrobulbarly 24 and 1 hours before the procedure and then in the same doses (0.5 ml of 1% solution ) 1 time per day for 2-10 days.


Increased individual sensitivity to the drug.

Side effects

Short-term agitation, drowsiness, increased hell, allergic reactions (skin rash, itching, redness), local reactions - pain, burning and hardening of paraorbital tissues (resolves independently).

special instructions

During treatment with Emoxypine, the state of the blood coagulation system and hell should be monitored.

Use during pregnancy and lactation. The use of the drug during pregnancy and lactation is contraindicated.

Children. The drug is not used in children.

The ability to influence the reaction rate when driving vehicles or other mechanisms. Caution should be exercised when driving vehicles or working with other mechanisms, since the drug can cause drowsiness, increased blood pressure.


The negative manifestations of the use of Emoxypine during therapy with other drugs have not been described. α-tocopherol acetate potentiates the antioxidant effect of Emoxypine.


Cases of overdose are not described. with an overdose, an increase in the severity of side effects of the drug, a violation of blood coagulation are possible. treatment: cancel the drug, conduct symptomatic therapy.

Storage conditions

In the original packaging at a temperature not exceeding 25 ° C.

Tags: Methylethylpyridinol hydrochloride